In 1983 PT. Dumex Indonesia was acquired by Alpharma, then the new company’s name was modified to be PT. Dumex – Alpharma Indonesia, and in 2001 it was changed to be PT. Alpharma, focusing in Ethical and OTC business.

By the acquisition of the International Division of Alpharma by Actavis since 2006, PT. Alpharma was changed to be PT. Actavis Indonesia.

Today, PT. Actavis Indonesia is a part of Actavis Generics and is focusing on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. In July 2015, Allergan, Plc announced it would sell the Generics division of the company (Actavis Generics) to Teva Pharmaceuticals for $40.5 billion, the transaction was completed in the beginning of Aug 2016.

Our portfolio is the best-in-class products that provide valuable treatments for the central nervous system, gastroenterology, women’s health, cardiovascular, oncology and anti-infective therapeutic categories, and operates the biggest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines in approximately 80 countries. Our R&D focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

With new spirit of new company and supported by broad portfolio products, and strengthen by the production facility that compliance to the GMP EU standard, ASEAN, and Indonesia, PT. Actavis Indonesia move aggressively and positioning as one of the biggest pharmaceutical company in Indonesia that committed to increasing access to quality health solutions, and has an unparalleled impact on patients and healthcare systems worldwide.